The FDA has forged a research partnership with the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) to spur innovation in advanced manufacturing.
The agreement is intended to move forward areas such as continuous manufacturing, on-demand manufacturing and advanced process control technologies. “Ultimately, advancements in these areas will…[enhance] patient access to new and improved medicines,” the institute said.
The FDA says the work with NIIMBL could lead to wide-ranging improvements in drug manufacturing.
“We are increasingly seeing the potential for advanced manufacturing innovations that can improve drug quality, help address shortages of medicines, speed time-to-market, and support personalized medicine,” said acting FDA Commissioner Ned Sharpless.